Metabolon, which is developing biomarker technology based on metabolomics, is now a member of the National Cancer Institute’s Early Detection Research Network.

The project is the second for Metabolon with the NCI but the first since being selected to become part of the early detection group. That group was established in 2000.

Metabolon will work with the University of Michigan to discover novel disease biomarkers related to prostate cancer.

The work will be funded by a grant for an undisclosed amount of money from the NCI.

“Membership in the EDRN is a great privilege,” said John Ryals, president and chief executive officer of Metabolon. “Metabolon will be able to collaborate with other members to discover and develop biomarkers for the early diagnosis of cancers.”